

Appendix 1: Search strategies [posted as supplied by author]

1. Medline (Ovid) (Search date: March 08, 2013)

- 1 glucagon like peptide*.ti,ab.
- 2 Receptors, Glucagon/ag [Agonists]
- 3 exenatide.af.
- 4 liraglutide.af.
- 5 albiglutide.af.
- 6 taspoglutide.af.
- 7 lixisenatide.af.
- 8 dulaglutide.af.
- 9 ZP10A peptide*.af.
- 10 GLP 1 Receptor Agonist*.af.
- 11 GLP 1 RA*.af.
- 12 GLP 1RA*.af.
- 13 dipeptidyl peptidase IV inhibit*.af.
- 14 Dipeptidyl Peptidase 4 Inhibit*.af.
- 15 DPP 4 inhibit*.af.
- 16 DPP4 inhibit*.af.
- 17 DPP4i.af.
- 18 DPP IV inhibit*.af.
- 19 DPPIV inhibit*.af.
- 20 alogliptin.af.
- 21 gemigliptin.af.
- 22 "LC15 0444".af.
- 23 linagliptin.af.
- 24 saxagliptin.af.
- 25 sitagliptin.af.
- 26 vildagliptin.af.
- 27 dutogliptin.af.
- 28 teneligliptin.af.
- 29 gliptin*.af.
- 30 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20
- or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29
- 31 (clinical trial or controlled clinical trial or randomized controlled trial).pt.
- 32 clinical trials as topic/ or controlled clinical trials as topic/ or randomized controlled trials as topic/
- 33 random*.ti,ab.
- 34 clinical trial*.ti,ab.
- 35 controlled trial*.ti,ab.
- 36 case-control studies/
- 37 retrospective studies/
- 38 cohort studies/
- 39 longitudinal studies/
- 40 follow-up studies/
- 41 prospective studies/
- 42 cohort.ti,ab.
- 43 longitudinal.ti,ab.
- 44 follow up.ti,ab.
- 45 followup.ti,ab.

46 prospective*.ti,ab.
 47 retrospective*.ti,ab.
 48 nonrandom*.ti,ab.
 49 comparison group*.ti,ab.
 50 control group*.ti,ab.
 51 database*.ti,ab.
 52 population*.ti,ab.
 53 registries/
 54 registry.ti,ab.
 55 registries.ti,ab.
 56 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38 or 39 or 40 or 41 or 42 or 43 or 44 or 45 or 46 or 47 or 48
 or 49 or 50 or 51 or 52 or 53 or 54 or 55
 57 30 and 56
 58 limit 57 to humans
 59 limit 57 to animals
 60 59 not 58
 61 57 not 60
 62 meta analysis.pt.
 63 Meta-Analysis as Topic/
 64 meta analy*.ti.
 65 metaanaly*.ti.
 66 62 or 63 or 64 or 65
 67 30 and 66
 68 limit 67 to humans
 69 limit 67 to animals
 70 69 not 68
 71 67 not 70
 72 61 not 71
 73 remove duplicates from 72
 74 remove duplicates from 71

2. Embase (Search date: March 26, 2013)

#48 #47 AND 'human'/de
 #47 #32 AND #46
 #46 #33 OR #34 OR #35 OR #36 OR #37 OR #38 OR #39 OR #40 OR #41 OR #42 OR #43 OR #44 OR #45
 #45 'registries'/exp
 #44 database*
 #43 'control group'/exp
 #42 'comparison group'
 #41 'prospective studies'/exp
 #40 nonrandom
 #39 'follow up studies'/exp
 #38 'longitudinal studies'/exp
 #37 'cohort studies'/exp
 #36 'retrospective studies'/exp
 #35 'case-control studies'/exp
 #34 random*
 #33 'clinical trial'/exp OR 'controlled clinical trial'/exp OR 'randomized controlled trial'/exp

#32 #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24 OR #25 OR #26 OR #27 OR #28 OR #29 OR #30 OR #31

#31 'gliptin'/exp

#30 'teneligliptin'/exp

#29 'dutogliptin'/exp

#28 'vildagliptin'/exp

#27 'sitagliptin'/exp

#26 'saxagliptin'/exp

#25 'linagliptin'/exp

#24 'lc15 0444'

#23 'gemigliptin'/exp

#22 'alogliptin'/exp

#21 'dppiv inhibitor'

#20 'dpp iv inhibitor'

#19 dpp4i

#18 'dpp 4 inhibitor'

#17 'dipeptidyl peptidase 4 inhibitor'/exp

#16 'dipeptidyl peptidase iv inhibitor'/exp

#15 'dipeptidyl peptidase iv inhibit'

#14 'glp 1 ra'

#13 'zp10a peptide 1'

#12 'zp10a peptide'

#11 'dulaglutide '/exp

#10 'lixisenatide'/exp

#9 'taspoglutide'/exp

#8 'albiglutide'/exp

#7 'liraglutide'/exp

#6 'exenatide'/exp

#5 'receptors, glucagon'/exp

#4 'glucagon like peptide 1 receptor agonists'

#3 'glp-1 receptor agonists'

#2 'glucagon like peptide 1'/exp

#1 'glucagon like peptide'/exp

3. Cochrane Central Register of Controlled Trials (Issue 2 of 12, Feb. 2013)

#1 (GLP next 1 next RA*):ti,ab,kw in Trials

#2 (GLP next 1RA*):ti,ab,kw in Trials

#3 exenatide.af.

#4 liraglutide.af.

#5 albiglutide.af.

#6 taspoglutide.af.

#7 lixisenatide.af.

#8 dulaglutide.af.

#9 (dipeptidyl next peptidase next IV next inhibit*):ti,ab,kw in Trials

#10 (Dipeptidyl next Peptidase next 4 next Inhibit*):ti,ab,kw in Trials

#11 (DPP next 4 next inhibit*):ti,ab,kw in Trials

#12 (DPP4 next inhibit*):ti,ab,kw in Trials

#13 DPP4i:ti,ab,kw in Trials
 #14 (DPP next IV next inhibit*):ti,ab,kw in Trials
 #15 (DPPIV next inhibit*):ti,ab,kw in Trials
 #16 alogliptin:ti,ab,kw in Trials
 #17 gemigliptin:ti,ab,kw in Trials
 #18 (LC15 next 0444):ti,ab,kw in Trials
 #19 linagliptin:ti,ab,kw in Trials
 #20 saxagliptin:ti,ab,kw in Trials
 #21 sitagliptin:ti,ab,kw in Trials
 #22 vildagliptin:ti,ab,kw in Trials
 #23 dutogliptin:ti,ab,kw in Trials
 #24 teneligliptin:ti,ab,kw in Trials
 #25 gliptin*:ti,ab,kw in Trials
 #26 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24 or #25 in Trials

4. ClinicalTrials.gov (Search date: August 16, 2013)

Completed | Studies With Results | exenatide OR liraglutide OR albiglutide OR taspoglutide OR lixisenatide OR dulaglutide OR sitagliptin OR vildagliptin OR saxagliptin OR linagliptin OR alogliptin OR dutogliptin OR gemigliptin OR teneligliptin

** In searching ClinicalTrials.gov, we did not include the general terms, such as “glucagon like peptide-1” and “dipeptidyl peptidase-4”, as this registry is designed so that one can capture relevant trials using generic drug names.